🧬Eli Lilly Signs $2.75B AI Drug Discovery Deal With Insilico Medicine
Eli Lilly Signs $2.75B AI Drug Discovery Deal With Insilico…
TL;DR
Eli Lilly struck a landmark agreement with Hong Kong-based Insilico Medicine worth up to $2.75 billion.
Eli Lilly struck a landmark agreement with Hong Kong-based Insilico Medicine worth up to $2.75 billion. Lilly gets exclusive worldwide rights to develop preclinical drug candidates discovered using Insilico's Pharma.AI generative platform, with $115 million upfront and the remainder tied to development, regulatory, and commercial milestones.
Key Points
Deal size up to $2.75B, $115M upfront
Exclusive worldwide rights to Insilico AI-generated preclinical candidates
Builds on Insilico's INS018_055 Phase IIa success in IPF
173+ AI-discovered programs now in clinical development industry-wide
Why It Matters
This is one of the largest outright AI-discovery licensing deals to date and signals that big pharma is willing to place billion-dollar bets on compounds designed mostly by machines.
Frequently Asked Questions
Why does this matter?
This is one of the largest outright AI-discovery licensing deals to date and signals that big pharma is willing to place billion-dollar bets on compounds designed mostly by machines.
What happened?
Eli Lilly struck a landmark agreement with Hong Kong-based Insilico Medicine worth up to $2.75 billion.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.